AVEO AVEO Pharmaceuticals Inc.

0  0%
Previous Close 0.66
Open 0.66
Price To Book 66.71
Market Cap 107,232,641
Shares 160,744,478
Volume 1,049,088
Short Ratio
Av. Daily Volume 2,572,477

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced December 7, 2017.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 data at ESMO 2018 noted 56% ORR.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
EGFR-mutated Non-small cell lung cancer (NSCLC)
Noted January 31, 2019 that FDA recommended against filing an NDA with current OS data. Additional interim OS analysis due August 2019 with further OS data 4Q 2019.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 1b poster presented at AACR April 1, 2019. 9/17 CRs.
Ficlatuzumab and cytarabine
Acute myeloid leukemia (AML)

Latest News

  1. AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
  2. AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
  3. AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update
  4. AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
  5. AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why
  6. Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
  7. AVEO (AVEO) Down 19.9% Since Last Earnings Report: Can It Rebound?
  8. AVEO Oncology to Present at the 2019 BIO International Convention
  9. AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
  10. AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
  11. AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
  12. AVEO: 1Q Earnings Snapshot
  13. AVEO Reports First Quarter 2019 Financial Results and Provides Business Update
  14. AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know
  15. AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
  16. AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
  17. FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  18. APRIL 26 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors Who Suffered Losses Exceeding $100,000 to Contact the Firm